Method and apparatus for predicting the presence of...

Chemistry: analytical and immunological testing – Clotting or clotting factor level tests

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C436S063000, C436S164000, C422S073000, C422S082050, C422S082090, C702S019000, C702S022000, C702S030000, C702S032000, C073S064410, C073S064430, C600S369000

Reexamination Certificate

active

10884293

ABSTRACT:
Methods for predicting the presence of haemostatic dysfunction in a patient from a time-dependent measurement profile include performing a time-dependent measurement on an unknown sample and measuring a respective property over time so as to derive a time-dependent measurement profile. The slope of the time-dependent measurement profile is computed prior to clot formation. A biphasic waveform is detected in the time-dependent measurement profile based on the computed slope. The presence of haemostatic dysfunction in the patient is predicted based on the detected biphasic waveform.

REFERENCES:
patent: 3307392 (1967-03-01), Owen et al.
patent: 3458287 (1969-07-01), Gross et al.
patent: 3658480 (1972-04-01), Kane et al.
patent: 4040788 (1977-08-01), Simons et al.
patent: 4047890 (1977-09-01), Eichelberger et al.
patent: 4199748 (1980-04-01), Bacus
patent: 4217107 (1980-08-01), Saito et al.
patent: 4279616 (1981-07-01), Saito et al.
patent: 4289498 (1981-09-01), Baughman et al.
patent: 4766083 (1988-08-01), Miyashita et al.
patent: 4782014 (1988-11-01), Serban et al.
patent: 4902630 (1990-02-01), Bennett et al.
patent: 4965725 (1990-10-01), Rutenberg
patent: 4998535 (1991-03-01), Selker et al.
patent: 5003065 (1991-03-01), Merritt et al.
patent: 5055412 (1991-10-01), Proksch
patent: 5156974 (1992-10-01), Grossman et al.
patent: 5169786 (1992-12-01), Carroll et al.
patent: 5218529 (1993-06-01), Meyer et al.
patent: 5221628 (1993-06-01), Anderson et al.
patent: 5358852 (1994-10-01), Wu
patent: 5388164 (1995-02-01), Yonekawa et al.
patent: 5473551 (1995-12-01), Sato et al.
patent: 5473732 (1995-12-01), Chang
patent: 5500345 (1996-03-01), Soe et al.
patent: 5506146 (1996-04-01), Josef
patent: 5525477 (1996-06-01), Hassouna
patent: 5526111 (1996-06-01), Collins et al.
patent: 5553616 (1996-09-01), Ham et al.
patent: 5563983 (1996-10-01), Nozaki et al.
patent: 5567596 (1996-10-01), Diamond et al.
patent: 5591403 (1997-01-01), Gavin et al.
patent: 5593897 (1997-01-01), Potempa et al.
patent: 5646046 (1997-07-01), Fischer et al.
patent: 5670329 (1997-09-01), Oberhardt
patent: 5705395 (1998-01-01), Griffin et al.
patent: 5708591 (1998-01-01), Givens et al.
patent: 5715821 (1998-02-01), Faupel
patent: 5716795 (1998-02-01), Matschiner
patent: 5834223 (1998-11-01), Griffin et al.
patent: 5856114 (1999-01-01), Mann et al.
patent: 5862304 (1999-01-01), Ravdin et al.
patent: 5981285 (1999-11-01), Carroll et al.
patent: 6010911 (2000-01-01), Baugh et al.
patent: 6040147 (2000-03-01), Ridker et al.
patent: 6101449 (2000-08-01), Givens et al.
patent: 6156530 (2000-12-01), R.ang.nby
patent: 6269313 (2001-07-01), Givens et al.
patent: 6321164 (2001-11-01), Braun et al.
patent: 6429017 (2002-08-01), Toh et al.
patent: 6898532 (2005-05-01), Toh et al.
patent: 2635081 (1978-02-01), None
patent: 3502 878 (1985-01-01), None
patent: 0 115 459 (1984-08-01), None
patent: 0 434 377 (1991-06-01), None
patent: 0 525 273 (1993-02-01), None
patent: 818 680 (1998-01-01), None
patent: 841 566 (1998-05-01), None
patent: 2364 453 (1976-09-01), None
patent: 2005014 (1979-04-01), None
patent: 59-203959 (1984-11-01), None
patent: 60-114768 (1985-06-01), None
patent: 61-272655 (1986-12-01), None
patent: 05-180835 (1991-12-01), None
patent: 06-027115 (1992-07-01), None
patent: 04-254760 (1992-09-01), None
patent: 06-249855 (1994-09-01), None
patent: 10-104239 (1996-09-01), None
patent: 2012877 (1991-04-01), None
patent: 2061953 (1996-06-01), None
patent: 2070327 (1996-12-01), None
patent: 590665 (1976-02-01), None
patent: 1076086 (1984-02-01), None
patent: 1691741 (1989-08-01), None
patent: 1777089 (1990-06-01), None
patent: WO 86/06840 (1986-11-01), None
patent: WO 89/09628 (1989-10-01), None
patent: WO 91/00872 (1991-01-01), None
patent: WO 91/01383 (1991-02-01), None
patent: WO 91/01497 (1991-02-01), None
patent: WO 91/02812 (1991-03-01), None
patent: WO 91/05874 (1991-05-01), None
patent: WO 91/08460 (1991-06-01), None
patent: WO 91/16453 (1991-10-01), None
patent: WO 93/07491 (1993-04-01), None
patent: WO 93/09438 (1993-05-01), None
patent: WO 93/24530 (1993-12-01), None
patent: WO 94/07145 (1994-03-01), None
patent: WO 94/11714 (1994-05-01), None
patent: WO 94/16095 (1994-07-01), None
patent: WO 95/05590 (1995-02-01), None
patent: WO 95/08121 (1995-03-01), None
patent: WOP 96/42018 (1995-09-01), None
patent: WO 95/30154 (1995-11-01), None
patent: WO 96/06624 (1996-03-01), None
patent: WO 96/14581 (1996-05-01), None
patent: WP 96/21740 (1996-07-01), None
patent: WO 96/41291 (1996-12-01), None
patent: WO 97/04317 (1997-02-01), None
patent: WO 97/20066 (1997-06-01), None
patent: WO 97/34698 (1997-09-01), None
patent: WO 98/09628 (1998-03-01), None
patent: WO 99/34208 (1999-07-01), None
patent: WO 99/47699 (1999-09-01), None
Toh et al. Abstract No. 316, British Society for Haematology, Harrogate, Apr. 14-17, 1997, p. 86.
3×15 Test Kit for Detection of Plasma Protein C Activity Using a Clotting End-Point, Product # ACC-45,American Diagnostica Inc., 1-2 (Feb. 1989).
Artherotech,VAP/CAD Lipoprotein Risk Assessment Tes and Sample of VAP Profile, http://www.artherotech.com/risk—assesment.html.
Astion, et al., Overtraining in neural networks that interpret clinical data,Clin. Chem., 39(9):1998-2004 (1993).
Astion, et al., The applicaiton of backpropagation neural networks to problems in pathology and laboratory medicine,Arch Pathol Lab Med., 116:995-1001 (Oct. 1992).
Baum and Haussler, What size net gives valid generalization?, Neural Computation, p. 81-89 (Jan. 1989).
Baumann et al., “Simulation of the extrinsic pathway of the plasmatic clotting system,”Haemostasis, 21:329-337 (1991).
Baumann, et al., Computerized analysis of the in vitro activation of the plasmatic clotting system,Haemostasis, 19:309-321 (1989).
Bluestein and Archer, The sensitivity, specificity and predictive value of diagnostic information: a guide for clinicians,Nurse Practitioner, 16(7):39-45 (Jul. 1991).
Boone et al., Neural networks in radiologic diagnosis,Investigative Radiology, 25(9):1013-1023 (Sep. 1990).
Brandt, et al., Effect of lupus anticoagulants on the activated partial thromboplastin time. Results of the College of American Pathologists survey program,Arch Pathol Lab Med., 115:109-114 (Feb. 1991).
Braun et al., Examination of prothrombin time (PT) and activated partial thromboplastin time (APTT) optical clot profiles using an automated thromobosis-hemostasis,Coagulation Methods Instrumentation and Quality Control, p. 1236, Abstract #1286 (1995).
Braun, et al., Properties of optical data from activated partial thromboplastin time and prothrombin time assays,Thromb Haemost., 78:1079-1087 (1997).
C. Downey, et al.Br. J. Haematol., 136: 18854 (1997).
Cabana, et al., Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins,J. Lipid Res., 30:39-49 (1989).
Cabana, et al., Inflammation-induced changes in rabbit CRP and plasma lipoproteins,J.Immunol., 130(4):1736-1742 (Apr. 1983).
Cabana, et al., Interaction of very low density lipoproteins (VLDL) with rabbit C- reactive protein,J.Immunol., 128(5):2342-2348 (May 1982).
Canivet, et al., Postoperative changes in lipid profile: their relations with inflammatory markers and endocrine mediators,Acta Anaesthesiol Belg., 40(4):263-268 (1989).
Carrol, et al., Ortho Educational Monograph,The Clot Signature and New Aspects in Coagulation Testing, Ortho Diagnostic Systems, Inc., p. 1-20 (1989).
Christner and Mortensen, Specificity of the binding interaction between human serum amyloid P-component and immobilized human C-reactive protein,J.Biol.Chem., 269(13):9760-9766 (Apr. 1994).
Dassen, et al. , Self-learning neural networks in electrocardiography,J.Electrocardiol., 23 Suppl:200-202 (1990).
de Beer, et al.,Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein, J.Exp.Med., 156:230-242 (Jul. 1982).
Dennis et al., Utility of prothrombin time waveform analysis in the routine clinical setting,Abstract Instruction and Submission Form, (Sep. 1999).
Downey et al.,Early Id

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method and apparatus for predicting the presence of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method and apparatus for predicting the presence of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and apparatus for predicting the presence of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3745644

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.